Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Jet milling

Jet milling is widely used in the pharmaceutical industry and remains the leading technology for particle size reduction and is most commonly used for having consistent and uniform particles during formulation.

Page
Read more

Our Experts

Exceptional people ensure exceptional projects.

Page
Read more

Papillon DPI

Ultra-affordable, multi-use blister DPI.

Page
Read more